Compare RENX & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | BRTX |
|---|---|---|
| Founded | 2021 | 1997 |
| Country | United States | United States |
| Employees | 38 | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 6.3M |
| IPO Year | N/A | 2015 |
| Metric | RENX | BRTX |
|---|---|---|
| Price | $2.05 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 527.8K | ★ 1.1M |
| Earning Date | 05-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.19 |
| 52 Week High | $3.48 | $2.04 |
| Indicator | RENX | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 48.35 |
| Support Level | $0.12 | $0.23 |
| Resistance Level | $3.15 | $0.32 |
| Average True Range (ATR) | 0.23 | 0.02 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 28.95 | 77.55 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates into four segments as of December 31, 2025: real estate development, technology, compost sales, and logistics.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.